Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Harrisburg Wellness Reporter.
Press releases published on June 17, 2025
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
GlobeNewswire
·
June 17, 2025
Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, …
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease
GlobeNewswire
·
June 17, 2025
The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson’s disease CSF and plasma exposures reinforce VTX3232’s potential as a once-daily oral therapy for neurodegenerative diseases VTX3232 …
Vireo Growth Inc. Provides Corporate Update Post Closing of All Merger Transactions
GlobeNewswire
·
June 17, 2025
MINNEAPOLIS, June 17, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today announced a series of corporate updates following the closing of all its previously-announced definitive merger agreements, which …
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions
GlobeNewswire
·
June 17, 2025
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it was …
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
GlobeNewswire
·
June 17, 2025
New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally Exhibiting at European Society of Organ Transplantation (ESOT) …
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
GlobeNewswire
·
June 17, 2025
CAMBRIDGE, Massachusetts, June 17, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with …
Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East
GlobeNewswire
·
June 17, 2025
REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty …
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting
GlobeNewswire
·
June 17, 2025
- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator of …
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
GlobeNewswire
·
June 17, 2025
– Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat showed a clinically meaningful reduction in …
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
GlobeNewswire
·
June 17, 2025
LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25) 71% of patients with complete response remained in complete response at ≥ 6 …
Tariffs and U.S.-Canada relations are the top financial concern for seniors: new research from HOOPP and Abacus Data
GlobeNewswire
·
June 17, 2025
TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- Geopolitical instability and the ongoing trade dispute with the United States have emerged as a major financial concern for Canadians and is having an impact on people’s retirement planning, according to the …
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
GlobeNewswire
·
June 17, 2025
- 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached - - Striking tumor reductions with 39% overall response rate and 81% disease …
Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42
GlobeNewswire
·
June 17, 2025
HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today congratulates its strategic partner …
Astrocyte Pharmaceuticals Announces Milestones in the Fight Against Concussions: Launch of Phase 2 Clinical Trial and New $3M NIH Grant
GlobeNewswire
·
June 17, 2025
GROTON, Conn., June 17, 2025 (GLOBE NEWSWIRE) -- Astrocyte Pharmaceuticals Inc., a clinical-stage biotechnology company today announced two major milestones that could change the way we protect brains from the damage caused by concussions and repeat head …
AscellaHealth Wins Business Change and Transformation Excellence Award at the Industry Eagles Awards 2025
GlobeNewswire
·
June 17, 2025
DUBLIN and BERWYN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- We are proud to announce that AscellaHealth has been awarded Gold in the Business Change and Transformation Excellence category at the Industry Eagles Awards 2025, held on 5th June 2025 at The …
Llusern Scientific Announces ISO 13485 Certification for its Point-of-Care Diagnostics System for Urinary Tract Infections
GlobeNewswire
·
June 17, 2025
CARDIFF, United Kingdom, June 17, 2025 (GLOBE NEWSWIRE) -- Llusern Scientific, a point-of-care diagnostics company, announces it has been awarded ISO 13485 certification for its Lodestar DX testing system, a rapid molecular diagnostic platform for urinary …
Captain T Cell Joins Bayer Co.Lab Berlin to Accelerate Autologous and Allogeneic TCR-T Cell Therapy Programs for Cancer Patients
GlobeNewswire
·
June 17, 2025
Berlin, Germany – June 17th, 2025 – Captain T Cell GmbH, a biotech company developing next-generation TCR-based cell therapies for patients with solid tumors, today announced that it has been selected for residency in the Bayer Co.Lab incubator in Berlin. …
Evosep Joins P4ML to Power World’s Largest Multi-Omic Human Health Study of Two Million Samples
GlobeNewswire
·
June 17, 2025
SAINT-MALO, France, June 17, 2025 (GLOBE NEWSWIRE) -- Evosep®, a global leader in robust, high-throughput proteomics technologies, has been selected as the proteomics platform provider for the P4ML - OMIC-Assist Study—the world’s largest multi-omic …
ONWARD Medical Builds Commercial Momentum for the ARC-EX System and Reinforces its Brain-Computer Interface Leadership in Q1 2025
GlobeNewswire
·
June 17, 2025
EINDHOVEN, the Netherlands, June 17, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord …
Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering
GlobeNewswire
·
June 17, 2025
New Taipei City, Taiwan, June 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (the “Company”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly …